SPD 451

Drug Profile

SPD 451

Alternative Names: Dopamine D1 agonists - Shire Pharmaceuticals; SPD451

Latest Information Update: 17 Jun 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CeNeS Pharmaceuticals
  • Developer CeNeS Pharmaceuticals; Shire Pharmaceutical Development
  • Class
  • Mechanism of Action Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 17 Jun 2004 Discontinued - Preclinical for Parkinson's disease in United Kingdom (unspecified route)
  • 25 Jun 2002 This compound is still in active development with Shire Pharmaceuticals
  • 03 Jan 2001 Shire Pharmaceuticals has entered into a licensing agreement with CeNes for the dopamine D1 agonist programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top